Wall Street Zen Downgrades Teva Pharmaceutical Industries (NYSE:TEVA) to Hold

Key Points

• Wall Street Zen downgraded Teva from "strong‑buy" to "hold", though the stock's consensus remains a Moderate Buy with an average price target of $41.56 (nine Buys, one Sell).
• Major brokers including UBS, Truist, Scotiabank and Barclays recently raised price targets and ratings, signaling analyst confidence and potential upside despite the downgrade.
• Q1 earnings beat—EPS $0.53 on $3.98B revenue driven by branded drugs (Austedo, Ajovy, Uzedy)—but generics weakness, insider selling and valuation/execution risks were highlighted.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "strong-buy" rating to a "hold" rating in a research report issued on Saturday.

A number of other research analysts have also weighed in on TEVA. Scotiabank raised their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a "sector outperform" rating in a research note on Thursday, January 29th. UBS Group raised their target price on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a "buy" rating in a research note on Thursday. Truist Financial raised their target price on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a "buy" rating in a research note on Thursday. Barclays raised their target price on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an "overweight" rating in a research note on Friday, January 30th. Finally, Bank of America raised their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a "buy" rating in a research note on Thursday, April 9th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $41.56.

Get TEVA SMS alerts:

Sign Up

Teva Pharmaceutical Industries Trading Down 0.2%

TEVA stock opened at $35.00 on Friday. The company has a current ratio of 1.01, a quick ratio of 0.80 and a debt-to-equity ratio of 1.70. Teva Pharmaceutical Industries has a 12-month low of $14.99 and a 12-month high of $37.35. The stock has a market cap of $40.24 billion, a price-to-earnings ratio of 26.31, a PEG ratio of 3.09 and a beta of 0.86. The business's 50-day moving average is $31.15 and its 200 day moving average is $29.33.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The business had revenue of $3.98 billion for the quarter. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries will post 2.6 EPS for the current fiscal year.

Insider Activity

In other news, insider Brian Savage sold 1,127 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $35,692.09. Following the sale, the insider owned 10,914 shares of the company's stock, valued at approximately $345,646.38. The trade was a 9.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric A. Hughes sold 9,533 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $301,910.11. Following the sale, the insider directly owned 107,711 shares in the company, valued at approximately $3,411,207.37. The trade was a 8.13% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 920,901 shares of company stock worth $30,056,789. 0.54% of the stock is owned by company insiders.

Institutional Trading of Teva Pharmaceutical Industries

Several institutional investors have recently made changes to their positions in the company. Candriam S.C.A. purchased a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter valued at approximately $14,083,000. Sequoia Financial Advisors LLC raised its position in shares of Teva Pharmaceutical Industries by 23.0% during the 1st quarter. Sequoia Financial Advisors LLC now owns 169,700 shares of the company's stock valued at $5,111,000 after buying an additional 31,756 shares during the period. Equitable Trust Co. purchased a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter valued at approximately $2,587,000. Hsbc Holdings PLC raised its position in shares of Teva Pharmaceutical Industries by 46.3% during the 1st quarter. Hsbc Holdings PLC now owns 961,140 shares of the company's stock valued at $28,789,000 after buying an additional 304,334 shares during the period. Finally, Range Financial Group LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter valued at approximately $332,000. Hedge funds and other institutional investors own 54.05% of the company's stock.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q1 earnings beat and revenue upside driven by branded products (Austedo, Ajovy, Uzedy), which lifted investor sentiment and underpins near‑term earnings growth. Read More.
• Positive Sentiment: Multiple broker upgrades and higher price targets — UBS, Truist, JPMorgan and Piper Sandler raised targets/ratings over the last day, signaling analyst confidence in a re‑rating and further upside for the stock. Read More. Read More.
• Positive Sentiment: Teva agreed to acquire Emalex for ~\$900M to add ecopipam (paediatric Tourette’s) — a late‑stage, de‑risked asset that bolsters the specialty/innovative portfolio and supports the narrative that Teva is shifting toward higher‑margin branded growth. Read More.
• Neutral Sentiment: Teva published its 2025 Healthy Future Report and says it met all sustainability‑linked bond targets — positive for ESG profile and potentially credit metrics, but unlikely to move near‑term revenues. Read More.
• Neutral Sentiment: Blackstone put significant financing behind Teva in a recent deal — signals institutional interest/validation but primarily affects capital structure and optionality rather than immediate EPS. Read More.
• Neutral Sentiment: Industry reports list Teva among leaders in oral solid dosage contract manufacturing — positive for long‑term service demand exposure but not an immediate earnings catalyst. Read More.
• Negative Sentiment: Generics revenue remains weak even as branded sales grow — raises questions about sustainability of overall top‑line growth if branded momentum slows. Read More.
• Negative Sentiment: After a rapid share run‑up, some analysts and coverage pieces note valuation/volatility risk — investors should weigh near‑term upside from upgrades against stretched multiples and execution risk. Read More.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.